Research Article

From Awareness to Implementation: Iron Deficiency Management in Heart Failure — A National Survey of Cardiologists in Türkiye

Volume: 52 September 10, 2026
TR EN

From Awareness to Implementation: Iron Deficiency Management in Heart Failure — A National Survey of Cardiologists in Türkiye

Abstract

Iron deficiency (ID) is a common comorbidity in heart failure (HF). Current guidelines recommend systematic assessment of iron status using ferritin and transferrin saturation (TSAT) and intravenous iron therapy for eligible patients. This study evaluated awareness, diagnostic practices, treatment preferences, and perceived barriers related to ID management among cardiologists in Türkiye. A national cross-sectional survey was conducted among cardiology residents, specialists, and academic cardiologists. An 11-item questionnaire assessed guideline awareness, diagnostic testing patterns, treatment practices, and barriers to intravenous iron use in patients with HF and reduced or mildly reduced ejection fraction. A total of 267 cardiologists were included. Most participants were familiar with contemporary recommendations for ID management in HF (94.4%). Ferritin (91.0%) and hemoglobin (88.4%) were the most frequently requested tests, whereas TSAT was routinely assessed by 63.3%. The European Society of Cardiology definition of ID was correctly identified by 61.4% of respondents. Routine TSAT use was strongly associated with correct recognition of guideline-defined ID (75.7% vs. 36.7%, p<0.001). Although intravenous iron was preferred by 73.8% of participants, only 22.5% reported routine administration. The main barriers were infusion logistics (51.3%), workload (44.6%), and reimbursement/reporting procedures (34.8%). Despite high awareness of ID among cardiologists, important gaps remain in the implementation of guideline-recommended diagnostic and therapeutic strategies. Underuse of TSAT and low rates of routine intravenous iron administration indicate that the major challenge in contemporary ID management is implementation rather than recognition.

Keywords

References

  1. 1. McDonagh, T. A., Metra, M., Adamo, M., Baumbach, A., Böhm, M., Burri, H., Čelutkiene, J., Chioncel, O., Cleland, J. G. F., Coats, A. J. S., Crespo-Leiro, M. G., Farmakis, D., Gardner, R. S., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., Lainscak, M., … Koskinas, K. C. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. In European Heart Journal (Vol. 42, Issue 36, pp. 3599–3726). Oxford University Press. https://doi.org/10.1093/eurheartj/ehab368
  2. 2. McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Celutkiene, J., Chioncel, O., Cleland, J. G. F., Crespo-Leiro, M. G., Farmakis, D., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., Lainscak, M., … Zeppenfeld, K. (2023). 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 44(37), 3627–3639. https://doi.org/10.1093/eurheartj/ehad195
  3. 3. Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., Kirwan, B.-A., Mori, C., von Eisenhart Rothe, B., Pocock, S. J., Poole-Wilson, P. A., & Ponikowski, P. (2009). Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. New England Journal of Medicine, 361(25), 2436–2448. https://doi.org/10.1056/nejmoa0908355
  4. 4. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J. 2015 Mar 14;36(11):657-68. doi: 10.1093/eurheartj/ehu385. Epub 2014 Aug 31. PMID: 25176939; PMCID: PMC4359359.
  5. 5. Ponikowski P, Kirwan B, Anker S et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial The Lancet, 2020; 396, 1895-1904
  6. 6. Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, She L, Harrington J, Adamczyk R, Blackman N, Hernandez AF; HEART-FID Investigators. Ferric Carboxymaltose in Heart Failure with Iron Deficiency. N Engl J Med. 2023 Sep 14;389(11):975-986. doi: 10.1056/NEJMoa2304968. Epub 2023 Aug 26. PMID: 37632463.
  7. 7. Anker SD, Friede T, Butler J, et al. Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial. JAMA. 2025;333(22):1965–1976. doi:10.1001/jama.2025.3833
  8. 8. Anker SD, Karakas M, Mentz RJ, Ponikowski P, Butler J, Khan MS, Talha KM, Kalra PR, Hernandez AF, Mulder H, Rockhold FW, Placzek M, Röver C, Cleland JGF, Friede T. Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med. 2025 Aug;31(8):2640-2646. doi: 10.1038/s41591-025-03671-1. Epub 2025 Mar 30. PMID: 40159279; PMCID: PMC12353798.

Details

Primary Language

English

Subjects

Haematology

Journal Section

Research Article

Publication Date

September 10, 2026

Submission Date

July 8, 2026

Acceptance Date

August 10, 2026

Published in Issue

Year 2026 Volume: 52

APA
Alak, Ç., & Günay, Ş. (2026). From Awareness to Implementation: Iron Deficiency Management in Heart Failure — A National Survey of Cardiologists in Türkiye. Journal of Uludağ University Medical Faculty, 52. https://doi.org/10.32708/uutfd.1989221
AMA
1.Alak Ç, Günay Ş. From Awareness to Implementation: Iron Deficiency Management in Heart Failure — A National Survey of Cardiologists in Türkiye. Journal of Uludağ University Medical Faculty. 2026;52. doi:10.32708/uutfd.1989221
Chicago
Alak, Çetin, and Şeyda Günay. 2026. “From Awareness to Implementation: Iron Deficiency Management in Heart Failure — A National Survey of Cardiologists in Türkiye”. Journal of Uludağ University Medical Faculty 52 (September). https://doi.org/10.32708/uutfd.1989221.
EndNote
Alak Ç, Günay Ş (September 1, 2026) From Awareness to Implementation: Iron Deficiency Management in Heart Failure — A National Survey of Cardiologists in Türkiye. Journal of Uludağ University Medical Faculty 52
IEEE
[1]Ç. Alak and Ş. Günay, “From Awareness to Implementation: Iron Deficiency Management in Heart Failure — A National Survey of Cardiologists in Türkiye”, Journal of Uludağ University Medical Faculty, vol. 52, Sept. 2026, doi: 10.32708/uutfd.1989221.
ISNAD
Alak, Çetin - Günay, Şeyda. “From Awareness to Implementation: Iron Deficiency Management in Heart Failure — A National Survey of Cardiologists in Türkiye”. Journal of Uludağ University Medical Faculty 52 (September 1, 2026). https://doi.org/10.32708/uutfd.1989221.
JAMA
1.Alak Ç, Günay Ş. From Awareness to Implementation: Iron Deficiency Management in Heart Failure — A National Survey of Cardiologists in Türkiye. Journal of Uludağ University Medical Faculty. 2026;52. doi:10.32708/uutfd.1989221.
MLA
Alak, Çetin, and Şeyda Günay. “From Awareness to Implementation: Iron Deficiency Management in Heart Failure — A National Survey of Cardiologists in Türkiye”. Journal of Uludağ University Medical Faculty, vol. 52, Sept. 2026, doi:10.32708/uutfd.1989221.
Vancouver
1.Çetin Alak, Şeyda Günay. From Awareness to Implementation: Iron Deficiency Management in Heart Failure — A National Survey of Cardiologists in Türkiye. Journal of Uludağ University Medical Faculty. 2026 Sep. 1;52. doi:10.32708/uutfd.1989221

ISSN: 1300-414X, e-ISSN: 2645-9027

Creative Commons License
Journal of Uludag University Medical Faculty is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2023